Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.
Frederik Hendrik VerbruggeAnne-Céline MartinDeborah SiegalKaren PieperLaura IllingworthA John CammKeith A A FoxPublished in: Heart (British Cardiac Society) (2019)
In contrast to guideline recommendations, almost half of real-world patients with AF at a very low thromboembolic risk according to the CHA2DS2-VASc score receive OAC. Persistent or permanent AF and increasing age up to 65 years are associated with OAC use, while concomitant antiplatelet therapy shows an inverse association. Regardless whether patients received OAC therapy, few thromboembolic and bleeding events occur, highlighting the low risk of this population.
Keyphrases
- atrial fibrillation
- antiplatelet therapy
- percutaneous coronary intervention
- end stage renal disease
- acute coronary syndrome
- ejection fraction
- chronic kidney disease
- prognostic factors
- newly diagnosed
- magnetic resonance
- magnetic resonance imaging
- stem cells
- venous thromboembolism
- patient reported outcomes
- mesenchymal stem cells
- cell therapy
- contrast enhanced
- breast cancer risk